EPO Knocks Down Trio of Geron Patent Claims

Law360, New York (June 14, 2006, 12:00 AM EDT) -- In another blow to Geron Corp., the European Patent Office has ruled in favor of Danish pharmaceutical giant Pharmexa A/S and invalidated three claims of the U.S. biotechnology company’s European patent related to telomerase-targeted cancer vaccines.

On Wednesday, Pharmexa announced that the EPO had rejected a trio of Geron’s patent claims involving peptide vaccines against telomerase, an enzyme that adds specific DNA sequence repeats to the ends of DNA strands.

"It was a clear decision, solidly based on the arguments Pharmexa has presented,” said Jakob Schmidt,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.